5 Biotech companies backed by ARCH Venture Partners, including Seaport Therapeutics, Be Biopharma.
ARCH Venture Partners — Biotech accounts for 23 tracked companies with verified cap-table data, 23 of which disclose round sizes totalling $5.8B. The median disclosed raise is $200M, and the largest is Beam Therapeutics at $1B, ahead of Mirador Therapeutics ($650M) and Vividion Therapeutics ($362M).
The names that recur most often on these portfolio cap tables are ARCH Venture Partners (23 companies), Nextech Invest (4 companies), Alexandria Venture Investments (4 companies), Mubadala Capital (4 companies), F-Prime Capital (4 companies), T. Rowe Price (3 companies). By latest disclosed round, the market skews Series B (9), Series A (8), Series C (4), IPO (1).
Companies tracked: 23
Disclosed funding total: $5.8B across 23 companies
Median disclosed raise: $200M
Largest raise: Beam Therapeutics — $1B
Stage mix: Series B 9 · Series A 8 · Series C 4 · IPO 1
Most recent dated round: 2026-06-01
Best funded ARCH Venture Partners — Biotech companies
